Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuti...
Chemomab Therapeutics Ltd. - American Depositary Shares (CMMB)
Company Research
Source: PR Newswire
The non-alcoholic fatty liver disease market size is supposed to grow during the forecast period owing to the expected launch of novel emerging therapies, which shall fuel the growth of the non-alcoholic fatty liver disease market during the forecast period, i.e., 2023–2032. LAS VEGAS , Jan. 22, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Fatty Liver Disease Market Insights report includes a comprehensive understanding of current treatment practices, NAFLD emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].Key Takeaways from the Non-Alcoholic Fatty Liver Disease Market ReportAccording to DelveInsight's analysis, the market size for NAFLD across the 7MM is expected to grow with a significant CAGR by 2032.DelveInsight's analysis reveals that in the US most cases of NAFLD are found to be in between 40-60 y
Show less
Read more
Impact Snapshot
Event Time:
CMMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMMB alerts
High impacting Chemomab Therapeutics Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CMMB
News
- Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateGlobeNewswire
- Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis [Yahoo! Finance]Yahoo! Finance
- Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisGlobeNewswire
- Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 [Yahoo! Finance]Yahoo! Finance
- Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024GlobeNewswire
CMMB
Sec Filings
- 3/28/24 - Form 20-F
- 3/11/24 - Form SC
- 3/7/24 - Form 6-K
- CMMB's page on the SEC website